Chemotherapy of Hodgkin's disease.
An overall perspective of chemotherapy for Hodgkin's disease has been presented with particular emphasis on the treatment options to be considered at each stage of the disease. In 1950, M. Vera Peters ended her paper on the 'radiological' treatment of Hodgkin's disease thus: 'In the light of present knowledge the diagnosis of Hodgkin's disease should not be regarded with despair and the patient treated as incurable.... If a single ray of hope emerges from this analysis, the treatment of the individual concerned is a challenge to the combined efforts of the radiotherapist, the physician and the surgeon' (Peters, 1950). Over the ensuing 40 years, substantial progress has been made, but any further improvement must begin with an increase in the proportion of patients for whom complete remission is achieved. Prospective comparisons of hybrid regimens against standard chemotherapy are in progress and the results of these trials will hopefully answer the question as to which is the optimal regimen in the primary treatment of advanced Hodgkin's disease. The advent of growth factors may allow for an increase in dose intensity, possibly improving the results further. The role of very intensive therapy with autologous bone marrow support remains to be defined and is currently being evaluated in different trial settings. Meanwhile, the quest for alternative, less toxic compounds goes on. The challenge continues.